PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16434618-0 2006 Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mitoxantrone 68-80 ATP binding cassette subfamily B member 1 Homo sapiens 0-30 16740770-3 2006 EXPERIMENTAL DESIGN: ABCB1-mediated transport in leukemic CD34+ CD38- cells compared with their normal counterparts was assessed by quantitating the effect of specific ABCB1 modulators (verapamil and PSC-833) on mitoxantrone retention [defined as efflux index (EI), intracellular mitoxantrone fluorescence intensity in the presence/absence of inhibitor]. Mitoxantrone 212-224 ATP binding cassette subfamily B member 1 Homo sapiens 21-26 16740770-3 2006 EXPERIMENTAL DESIGN: ABCB1-mediated transport in leukemic CD34+ CD38- cells compared with their normal counterparts was assessed by quantitating the effect of specific ABCB1 modulators (verapamil and PSC-833) on mitoxantrone retention [defined as efflux index (EI), intracellular mitoxantrone fluorescence intensity in the presence/absence of inhibitor]. Mitoxantrone 280-292 ATP binding cassette subfamily B member 1 Homo sapiens 21-26 16740770-4 2006 RESULTS: ABCB1 was the major drug transporter in CD34+ CD38- cells in normal bone marrow (n = 16), as shown by the abrogation of mitoxantrone extrusion by ABCB1 modulators (EI, 1.99 +/- 0.08). Mitoxantrone 129-141 ATP binding cassette subfamily B member 1 Homo sapiens 9-14 16740770-4 2006 RESULTS: ABCB1 was the major drug transporter in CD34+ CD38- cells in normal bone marrow (n = 16), as shown by the abrogation of mitoxantrone extrusion by ABCB1 modulators (EI, 1.99 +/- 0.08). Mitoxantrone 129-141 ATP binding cassette subfamily B member 1 Homo sapiens 155-160 16740770-5 2006 Surprisingly, ABCB1-mediated drug extrusion was invariably reduced in CD34+ CD38- cells in AML (n = 15; EI, 1.21 +/- 0.05; P < 0.001), which resulted in increased intracellular mitoxantrone retention in these cells (mitoxantrone fluorescence intensity, 4.54 +/- 0.46 versus 3.08 +/- 0.23; P = 0.004). Mitoxantrone 180-192 ATP binding cassette subfamily B member 1 Homo sapiens 14-19 16740770-5 2006 Surprisingly, ABCB1-mediated drug extrusion was invariably reduced in CD34+ CD38- cells in AML (n = 15; EI, 1.21 +/- 0.05; P < 0.001), which resulted in increased intracellular mitoxantrone retention in these cells (mitoxantrone fluorescence intensity, 4.54 +/- 0.46 versus 3.08 +/- 0.23; P = 0.004). Mitoxantrone 219-231 ATP binding cassette subfamily B member 1 Homo sapiens 14-19 16434618-0 2006 Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mitoxantrone 68-80 ATP binding cassette subfamily B member 1 Homo sapiens 32-36 16434618-3 2006 This MRP1-associated reduced accumulation of MX was partially reversed by treatment of cells with 50 microM MK571 [3-[[3-[2-(7-chloroquinolin-2-yl)vinyl]phenyl]-(2-dimethylcarbamoylethylsulfanyl)methylsulfanyl] propionic acid]-an MRP inhibitor that increased MX accumulation in MRP1-expressing MCF7 cells but had no effect on MRP-poor MCF7 cells. Mitoxantrone 45-47 ATP binding cassette subfamily B member 1 Homo sapiens 5-9 16434618-3 2006 This MRP1-associated reduced accumulation of MX was partially reversed by treatment of cells with 50 microM MK571 [3-[[3-[2-(7-chloroquinolin-2-yl)vinyl]phenyl]-(2-dimethylcarbamoylethylsulfanyl)methylsulfanyl] propionic acid]-an MRP inhibitor that increased MX accumulation in MRP1-expressing MCF7 cells but had no effect on MRP-poor MCF7 cells. Mitoxantrone 45-47 ATP binding cassette subfamily B member 1 Homo sapiens 278-282 16434618-3 2006 This MRP1-associated reduced accumulation of MX was partially reversed by treatment of cells with 50 microM MK571 [3-[[3-[2-(7-chloroquinolin-2-yl)vinyl]phenyl]-(2-dimethylcarbamoylethylsulfanyl)methylsulfanyl] propionic acid]-an MRP inhibitor that increased MX accumulation in MRP1-expressing MCF7 cells but had no effect on MRP-poor MCF7 cells. Mitoxantrone 259-261 ATP binding cassette subfamily B member 1 Homo sapiens 5-9 16434618-7 2006 Together, these data are consistent with the interpretation that MX efflux by MRP1 involves cotransport of MX and glutathione. Mitoxantrone 65-67 ATP binding cassette subfamily B member 1 Homo sapiens 78-82 12687290-6 2003 RESULTS: Ketotifen was found to restore the sensitivity of P-glycoprotein-overexpressing multidrug-resistant MCF-7/adr cells to doxorubicin, mitoxantrone, VP-16 and vinblastine, but not to methotrexate or camptothecin. Mitoxantrone 141-153 ATP binding cassette subfamily B member 1 Homo sapiens 59-73 15920909-0 2005 Induction of the ABC-transporters Mdr1/P-gp (Abcb1), mrpl (Abcc1), and bcrp (Abcg2) during establishment of multidrug resistance following exposure to mitoxantrone. Mitoxantrone 151-163 ATP binding cassette subfamily B member 1 Homo sapiens 34-38 15920909-0 2005 Induction of the ABC-transporters Mdr1/P-gp (Abcb1), mrpl (Abcc1), and bcrp (Abcg2) during establishment of multidrug resistance following exposure to mitoxantrone. Mitoxantrone 151-163 ATP binding cassette subfamily B member 1 Homo sapiens 45-50 15920909-1 2005 Resistance to mitoxantrone is often associated with enhanced drug efflux mediated by members of the superfamily of adenosinetriphosphate-binding cassette (ABC) transporters, i.e. MDR1/P-gp (ABCB1), MRP1 (ABCC1), or BCRP (ABCG2). Mitoxantrone 14-26 ATP binding cassette subfamily B member 1 Homo sapiens 179-183 15920909-1 2005 Resistance to mitoxantrone is often associated with enhanced drug efflux mediated by members of the superfamily of adenosinetriphosphate-binding cassette (ABC) transporters, i.e. MDR1/P-gp (ABCB1), MRP1 (ABCC1), or BCRP (ABCG2). Mitoxantrone 14-26 ATP binding cassette subfamily B member 1 Homo sapiens 190-195 15920909-3 2005 Here, we demonstrate that the expression of all three extrusion pumps is induced by increasing levels of mitoxantrone resistance, but in the end, merely the overexpression of a dominant single drug transporter, i.e. Mdr1/P-gp, is realized. Mitoxantrone 105-117 ATP binding cassette subfamily B member 1 Homo sapiens 216-220 15920909-5 2005 Short mitoxantrone exposure demonstrated that upregulation of two different transporters, Mdr1/P-gp and Bcrp, was induced. Mitoxantrone 6-18 ATP binding cassette subfamily B member 1 Homo sapiens 90-94 15788683-6 2005 RESULTS: Cyclosporin A enhanced retention of the substrate drug mitoxantrone in cells overexpressing Pgp (HL60/VCR), MRP-1 (HL60/ADR), and BCRP (8226/MR20, HEK-293 482R) and increased cytotoxicity 6-, 4-, 4-, and 3-fold, respectively. Mitoxantrone 64-76 ATP binding cassette subfamily B member 1 Homo sapiens 101-104 15167906-0 2004 A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes. Mitoxantrone 77-89 ATP binding cassette subfamily B member 1 Homo sapiens 93-107 11809686-5 2002 Our data showed that the expression of MRP1-EGFP results in significantly decreased cellular accumulation of tetramethylrhodamine ethyl ester (TMRE) and daunorubicin, mildly decreased cellular accumulation of mitoxantrone, and decreased nuclear accumulation of doxorubicin. Mitoxantrone 209-221 ATP binding cassette subfamily B member 1 Homo sapiens 39-43 12136248-7 2002 RESULTS: In mitoxantrone-selected EPP85-181RNOV cells a decreased accumulation of mitoxantrone and daunorubicin was observed in the absence of P-glycoprotein, multidrug resistance protein or breast cancer resistance protein over-expression. Mitoxantrone 12-24 ATP binding cassette subfamily B member 1 Homo sapiens 143-157 12415630-2 2002 METHODS: We investigated if P-gp expression by cancer cells affects cell cytotoxicity and cell-cycle perturbations induced by six commonly used chemotherapeutic agents (doxorubicin, daunorubicin, mitoxantrone, vinblastine, paclitaxel, and colchicine). Mitoxantrone 196-208 ATP binding cassette subfamily B member 1 Homo sapiens 28-32 9933132-6 1999 With mitozantrone significant responses were seen in both Pgp positive and negative groups suggesting that the responses were due to direct cytotoxicity of the cytotoxic-modifier combination rather than reversal of MDR. Mitoxantrone 5-17 ATP binding cassette subfamily B member 1 Homo sapiens 58-61 10342576-1 1999 Ways of restoring an altered drug sensitivity in P-170 glycoprotein (MDR1) positive leukemias are being actively sought for, mostly using MDRI negative regulators together with the MDR1-sensitive anthracycline-type drugs daunorubicin and mitoxantrone. Mitoxantrone 238-250 ATP binding cassette subfamily B member 1 Homo sapiens 69-73 10342576-1 1999 Ways of restoring an altered drug sensitivity in P-170 glycoprotein (MDR1) positive leukemias are being actively sought for, mostly using MDRI negative regulators together with the MDR1-sensitive anthracycline-type drugs daunorubicin and mitoxantrone. Mitoxantrone 238-250 ATP binding cassette subfamily B member 1 Homo sapiens 181-185 10070941-1 1999 BACKGROUND: Human cancer cell lines grown in the presence of the cytotoxic agent mitoxantrone frequently develop resistance associated with a reduction in intracellular drug accumulation without increased expression of the known drug resistance transporters P-glycoprotein and multidrug resistance protein (also known as multidrug resistance-associated protein). Mitoxantrone 81-93 ATP binding cassette subfamily B member 1 Homo sapiens 258-272 9447822-0 1997 Cellular pharmacology of mitoxantrone in p-glycoprotein-positive and -negative human myeloid leukemic cell lines. Mitoxantrone 25-37 ATP binding cassette subfamily B member 1 Homo sapiens 41-55 9685354-3 1998 Expression of MRP1 alone confers resistance to several drugs representing the multidrug resistance phenotype, drugs including doxorubicin, vincristine, etoposide, and mitoxantrone. Mitoxantrone 167-179 ATP binding cassette subfamily B member 1 Homo sapiens 14-18 9615755-1 1998 The anthracenedione, mitoxantrone, frequently selects for a unique drug resistance phenotype that is not mediated by either MDR 1, MRP, or altered DNA topoisomerase II. Mitoxantrone 21-33 ATP binding cassette subfamily B member 1 Homo sapiens 124-129 9447822-2 1997 In order to determine the role of p-glycoprotein in the cellular pharmacology of mitoxantrone flow cytometry and confocal microscopy were used to study two human myeloid leukemia cell lines selected for resistance to mitoxantrone (HL-60MX2) and doxorubicin (HL-60DOX). Mitoxantrone 81-93 ATP binding cassette subfamily B member 1 Homo sapiens 34-48 9447822-7 1997 In contrast, 3.1- and 2.4-fold increases were found in uptake and retention of mitoxantrone in p-glycoprotein-positive cells (HL-60DOX) incubated with verapamil. Mitoxantrone 79-91 ATP binding cassette subfamily B member 1 Homo sapiens 95-109 9447822-11 1997 Our study demonstrates that the cellular pharmacology of mitoxantrone is affected by p-glycoprotein and can be reversed at least in part by verapamil. Mitoxantrone 57-69 ATP binding cassette subfamily B member 1 Homo sapiens 85-99 7664272-1 1995 We have previously described a mitoxantrone-resistant human breast carcinoma cell line, MCF7/MX, in which resistance was associated with a defect in the energy-dependent accumulation of mitoxantrone in the absence of P-glycoprotein overexpression (M. Nakagawa et al., Cancer Res. Mitoxantrone 31-43 ATP binding cassette subfamily B member 1 Homo sapiens 217-231 9180292-1 1997 In the present study it was investigated whether and by which mechanisms the co-administration of interleukin-3 (IL-3) and the P-glycoprotein blocker PSC 833 can augment mitoxantrone (MX) and daunorubicin (DAU) cytotoxicity in two human growth factor dependent P-glycoprotein (P-gp) positive myeloid leukemic cell lines, Mo-7 and GF-D8. Mitoxantrone 170-182 ATP binding cassette subfamily B member 1 Homo sapiens 127-141 9180292-1 1997 In the present study it was investigated whether and by which mechanisms the co-administration of interleukin-3 (IL-3) and the P-glycoprotein blocker PSC 833 can augment mitoxantrone (MX) and daunorubicin (DAU) cytotoxicity in two human growth factor dependent P-glycoprotein (P-gp) positive myeloid leukemic cell lines, Mo-7 and GF-D8. Mitoxantrone 184-186 ATP binding cassette subfamily B member 1 Homo sapiens 127-141 7906380-0 1994 Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: initial response and relationship to multidrug resistance gene 1. Mitoxantrone 25-37 ATP binding cassette subfamily B member 1 Homo sapiens 131-158 8185674-2 1994 Mitoxantrone, an anthracenedione antitumor agent, frequently selects for non-P-glycoprotein-mediated multidrug resistance in in vitro models. Mitoxantrone 0-12 ATP binding cassette subfamily B member 1 Homo sapiens 77-91 1350249-7 1992 Among the six evaluable cases tested with mitoxantrone and CyA, an increase of 50% in CFU-L sensitivity to mitoxantrone was noted in one (of three) P-gp+ patient. Mitoxantrone 42-54 ATP binding cassette subfamily B member 1 Homo sapiens 148-152 1350249-7 1992 Among the six evaluable cases tested with mitoxantrone and CyA, an increase of 50% in CFU-L sensitivity to mitoxantrone was noted in one (of three) P-gp+ patient. Mitoxantrone 107-119 ATP binding cassette subfamily B member 1 Homo sapiens 148-152 26651362-10 2016 Furthermore, the compounds atenolol, citalopram, and mitoxantrone were identified as P-gp substrates. Mitoxantrone 53-65 ATP binding cassette subfamily B member 1 Homo sapiens 85-89 2894893-10 1988 The limited cross-resistant phenotype, lack of verapamil reversal, nondetection of P-glycoprotein, and cytogenetic evidence of gene amplification suggests the involvement of a novel drug-resistant gene associated with resistance to mitoxantrone. Mitoxantrone 232-244 ATP binding cassette subfamily B member 1 Homo sapiens 83-97 31476282-5 2019 Further mechanism studies demonstrated that 479 increased the accumulation of paclitaxel and mitoxantrone in cancer cells by interrupting the efflux function of transporters and stimulating ABCB1/ABCG2 ATPase activity. Mitoxantrone 93-105 ATP binding cassette subfamily B member 1 Homo sapiens 190-195 30353640-5 2019 In this assay, fluorescent reporter substrates (Calcein-AM for MDR1 and MRP1 and mitoxantrone for BCRP, respectively) are trapped in the cytoplasm and pumped out by MDR proteins depending on the presence or absence of specific inhibitors (verapamil for MDR1 and MRP1, indomethacin for MRP1 and KO134 for BCRP, respectively), allowing for quantitative, standardized assessment. Mitoxantrone 81-93 ATP binding cassette subfamily B member 1 Homo sapiens 63-67 30353640-5 2019 In this assay, fluorescent reporter substrates (Calcein-AM for MDR1 and MRP1 and mitoxantrone for BCRP, respectively) are trapped in the cytoplasm and pumped out by MDR proteins depending on the presence or absence of specific inhibitors (verapamil for MDR1 and MRP1, indomethacin for MRP1 and KO134 for BCRP, respectively), allowing for quantitative, standardized assessment. Mitoxantrone 81-93 ATP binding cassette subfamily B member 1 Homo sapiens 253-257 31039321-7 2019 Mitoxantrone, daunorubicin, and vinorelbine are substrates of one or more of the ABCG2, ABCB1, or ABCC1 efflux transporters expressed to varying extents in the selected cell lines. Mitoxantrone 0-12 ATP binding cassette subfamily B member 1 Homo sapiens 88-93 30544754-7 2018 In this connection, LS-2-3j significantly enhanced the activity of chemotherapeutic drugs in MDR cells and could significantly increase the intracellular accumulation of doxorubicin (DOX) and mitoxantrone (MITX) by inhibiting the function of the efflux pumps in ABCB1- or ABCG2-overexpressing cells. Mitoxantrone 206-210 ATP binding cassette subfamily B member 1 Homo sapiens 262-267 28912036-6 2017 Indeed, ZSTK474 increased the cellular accumulation of calcein-AM and mitoxantrone in cells expressing ABCB1 and ABCG2, respectively. Mitoxantrone 70-82 ATP binding cassette subfamily B member 1 Homo sapiens 103-108 28712845-5 2017 These agents block transporter mediated efflux of the P-gp substrate calcein-AM and the ABCG2 substrate mitoxantrone. Mitoxantrone 104-116 ATP binding cassette subfamily B member 1 Homo sapiens 54-58 27479651-6 2016 The expression of P-gp was induced in SKM-1 cells by selective pressure using vincristine (VCR), mitoxantrone (MTX), azacytidine (AzaC) and lenalidomide (LEN). Mitoxantrone 97-109 ATP binding cassette subfamily B member 1 Homo sapiens 18-22 27479651-6 2016 The expression of P-gp was induced in SKM-1 cells by selective pressure using vincristine (VCR), mitoxantrone (MTX), azacytidine (AzaC) and lenalidomide (LEN). Mitoxantrone 111-114 ATP binding cassette subfamily B member 1 Homo sapiens 18-22 27479651-7 2016 Whereas the selective pressure of VCR, MTX and AzaC also induced P-gp expression in MOLM-13 cells, LEN was found to be ineffective in this regard. Mitoxantrone 39-42 ATP binding cassette subfamily B member 1 Homo sapiens 65-69 26622052-9 2016 Similarly, coexpression of human P-gp and ABCG2 in LLC-PK1 cells resulted in higher transport of mitoxantrone, which is a substrate for both transporters, than in either P-gp- or ABCG2-expressing cells alone. Mitoxantrone 97-109 ATP binding cassette subfamily B member 1 Homo sapiens 33-37 26622052-9 2016 Similarly, coexpression of human P-gp and ABCG2 in LLC-PK1 cells resulted in higher transport of mitoxantrone, which is a substrate for both transporters, than in either P-gp- or ABCG2-expressing cells alone. Mitoxantrone 97-109 ATP binding cassette subfamily B member 1 Homo sapiens 170-174 33378196-0 2021 (+/-)-Borneol Reverses Mitoxantrone Resistance against P-Glycoprotein. Mitoxantrone 23-35 ATP binding cassette subfamily B member 1 Homo sapiens 55-69 33378196-5 2021 In this work, the effect and molecular mechanism of borneol enantiomers in reversing mitoxantrone (MTO) resistance against Pgp were explored by in vitro and in silico approaches. Mitoxantrone 85-97 ATP binding cassette subfamily B member 1 Homo sapiens 123-126 33378196-5 2021 In this work, the effect and molecular mechanism of borneol enantiomers in reversing mitoxantrone (MTO) resistance against Pgp were explored by in vitro and in silico approaches. Mitoxantrone 99-102 ATP binding cassette subfamily B member 1 Homo sapiens 123-126 33378196-8 2021 Molecular docking revealed that BNLs could reduce the binding affinity between MTO and Pgp. Mitoxantrone 79-82 ATP binding cassette subfamily B member 1 Homo sapiens 87-90 31048454-5 2019 B1/G2 cells were also cross-resistant to the ABCB1 substrate doxorubicin, the ABCG2 substrate topotecan, as well as mitoxantrone and the cell cycle checkpoint kinase 1 inhibitor prexasertib, both of which were found to be substrates of both ABCB1 and ABCG2. Mitoxantrone 116-128 ATP binding cassette subfamily B member 1 Homo sapiens 241-246 31048454-7 2019 ABCB1 and ABCG2 also functioned additively to transport the common fluorescent substrates mitoxantrone and BODIPY-prazosin, as it was necessary to inhibit both transporters to prevent efflux from B1/G2 cells. Mitoxantrone 90-102 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 26002042-0 2015 Selection of resistant acute myeloid leukemia SKM-1 and MOLM-13 cells by vincristine-, mitoxantrone- and lenalidomide-induced upregulation of P-glycoprotein activity and downregulation of CD33 cell surface exposure. Mitoxantrone 87-99 ATP binding cassette subfamily B member 1 Homo sapiens 142-156 26002042-7 2015 However, in MOLM-13 cells, the upregulation of P-gp and downregulation of CD33 were present only in cells selected for resistance to vincristine and mitoxantrone but not lenalidomide. Mitoxantrone 149-161 ATP binding cassette subfamily B member 1 Homo sapiens 47-51 24305879-8 2014 Drug transport assays show that wild-type and haplotype P-gp respond differently to P-gp inhibitors that block efflux of rhodamine 123 or mitoxantrone. Mitoxantrone 138-150 ATP binding cassette subfamily B member 1 Homo sapiens 56-60 26002514-1 2015 BACKGROUND: A median fluorescence intensity ratio (MFIR) which measures the efflux of mitoxantrone (an ATP Binding Cassette (ABC) transporter substrate) with and without ABC transporter inhibition correlates with expression of MDR1 and BCRP in acute myeloid leukemia (AML) blasts. Mitoxantrone 86-98 ATP binding cassette subfamily B member 1 Homo sapiens 227-231 24305879-8 2014 Drug transport assays show that wild-type and haplotype P-gp respond differently to P-gp inhibitors that block efflux of rhodamine 123 or mitoxantrone. Mitoxantrone 138-150 ATP binding cassette subfamily B member 1 Homo sapiens 84-88 24305879-9 2014 In addition, cytotoxicity assays show that the LLC-MDR1-3H cells are more resistant to mitoxantrone than the LLC-MDR1-WT cells after being treated with a P-gp inhibitor. Mitoxantrone 87-99 ATP binding cassette subfamily B member 1 Homo sapiens 51-55 24305879-9 2014 In addition, cytotoxicity assays show that the LLC-MDR1-3H cells are more resistant to mitoxantrone than the LLC-MDR1-WT cells after being treated with a P-gp inhibitor. Mitoxantrone 87-99 ATP binding cassette subfamily B member 1 Homo sapiens 154-158 19423841-2 2009 We report using confocal microscopy to study the roles of Pgp in mediating the efflux of the anticancer agent mitoxantrone and the reversal of MDR by the specific Pgp inhibitor valspodar (PSC833). Mitoxantrone 110-122 ATP binding cassette subfamily B member 1 Homo sapiens 58-61 22451016-11 2012 Since mitoxantrone is a substrate of the efflux transporters ABCG2 and ABCB1, the incorporation of efflux transporters may also be necessary to characterize the data obtained in low-dose studies. Mitoxantrone 6-18 ATP binding cassette subfamily B member 1 Homo sapiens 71-76 20535833-8 2010 Interestingly, it was found that the intracellular fluorescence of mitoxantrone was decreased 31.9% when co-incubated with 10 microM biochanin A in P-glycoprotein (P-gp) expressing MCF-7/ADR cells, indicating potential P-gp stimulation. Mitoxantrone 67-79 ATP binding cassette subfamily B member 1 Homo sapiens 148-162 20535833-8 2010 Interestingly, it was found that the intracellular fluorescence of mitoxantrone was decreased 31.9% when co-incubated with 10 microM biochanin A in P-glycoprotein (P-gp) expressing MCF-7/ADR cells, indicating potential P-gp stimulation. Mitoxantrone 67-79 ATP binding cassette subfamily B member 1 Homo sapiens 164-168 20535833-8 2010 Interestingly, it was found that the intracellular fluorescence of mitoxantrone was decreased 31.9% when co-incubated with 10 microM biochanin A in P-glycoprotein (P-gp) expressing MCF-7/ADR cells, indicating potential P-gp stimulation. Mitoxantrone 67-79 ATP binding cassette subfamily B member 1 Homo sapiens 219-223 19423841-4 2009 The MDR cells, transduced with the human Pgp-encoding gene MDR1 construct, were approximately 8-fold more resistant to mitoxantrone than the wild-type cells. Mitoxantrone 119-131 ATP binding cassette subfamily B member 1 Homo sapiens 41-44 19423841-4 2009 The MDR cells, transduced with the human Pgp-encoding gene MDR1 construct, were approximately 8-fold more resistant to mitoxantrone than the wild-type cells. Mitoxantrone 119-131 ATP binding cassette subfamily B member 1 Homo sapiens 59-63 18829547-6 2008 Additionally, lapatinib significantly increased the accumulation of doxorubicin or mitoxantrone in ABCB1- or ABCG2-overexpressing cells and inhibited the transport of methotrexate and E(2)17betaG by ABCG2. Mitoxantrone 83-95 ATP binding cassette subfamily B member 1 Homo sapiens 99-104 19333870-3 2009 In recent years, ATP-binding cassette (ABC) transporters related to multidrug resistance (MDR), such as P-glycoprotein (P-gp; ABCB1/MDR1) and ABCG2 (breast cancer resistance protein/mitoxantrone resistance protein) have emerged as key factors that regulate the intracellular concentrations of many small-molecule therapeutic inhibitors. Mitoxantrone 182-194 ATP binding cassette subfamily B member 1 Homo sapiens 104-118 19333870-3 2009 In recent years, ATP-binding cassette (ABC) transporters related to multidrug resistance (MDR), such as P-glycoprotein (P-gp; ABCB1/MDR1) and ABCG2 (breast cancer resistance protein/mitoxantrone resistance protein) have emerged as key factors that regulate the intracellular concentrations of many small-molecule therapeutic inhibitors. Mitoxantrone 182-194 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 19333870-3 2009 In recent years, ATP-binding cassette (ABC) transporters related to multidrug resistance (MDR), such as P-glycoprotein (P-gp; ABCB1/MDR1) and ABCG2 (breast cancer resistance protein/mitoxantrone resistance protein) have emerged as key factors that regulate the intracellular concentrations of many small-molecule therapeutic inhibitors. Mitoxantrone 182-194 ATP binding cassette subfamily B member 1 Homo sapiens 126-131 19333870-3 2009 In recent years, ATP-binding cassette (ABC) transporters related to multidrug resistance (MDR), such as P-glycoprotein (P-gp; ABCB1/MDR1) and ABCG2 (breast cancer resistance protein/mitoxantrone resistance protein) have emerged as key factors that regulate the intracellular concentrations of many small-molecule therapeutic inhibitors. Mitoxantrone 182-194 ATP binding cassette subfamily B member 1 Homo sapiens 132-136 17900739-2 2007 To examine whether some currently used excipients could inhibit its function, we measured the uptake of [(3)H]mitoxantrone in BCRP-, P-glycoprotein (P-gp)- or green fluorescent protein (GFP)-expressing cells, in the presence or absence of 15 kinds of currently used excipients. Mitoxantrone 110-122 ATP binding cassette subfamily B member 1 Homo sapiens 133-147 18718123-4 2008 Treatment with transporter inhibitors MK571, quinidine or mitoxantrone, which inhibit MRP2, P-glycoprotein (P-gp) and BCRP, respectively, led to an increase in the accumulation of EC into Caco-2 cells and a decrease in the Papp ratio (Papp B-->A/Papp A-->B) for EC. Mitoxantrone 58-70 ATP binding cassette subfamily B member 1 Homo sapiens 92-106 18718123-4 2008 Treatment with transporter inhibitors MK571, quinidine or mitoxantrone, which inhibit MRP2, P-glycoprotein (P-gp) and BCRP, respectively, led to an increase in the accumulation of EC into Caco-2 cells and a decrease in the Papp ratio (Papp B-->A/Papp A-->B) for EC. Mitoxantrone 58-70 ATP binding cassette subfamily B member 1 Homo sapiens 108-112 17900739-2 2007 To examine whether some currently used excipients could inhibit its function, we measured the uptake of [(3)H]mitoxantrone in BCRP-, P-glycoprotein (P-gp)- or green fluorescent protein (GFP)-expressing cells, in the presence or absence of 15 kinds of currently used excipients. Mitoxantrone 110-122 ATP binding cassette subfamily B member 1 Homo sapiens 149-153 18006847-4 2007 Our findings show that erlotinib significantly potentiated the sensitivity of established ABCB1 or ABCG2 substrates and increased the accumulation of paclitaxel or mitoxantrone in ABCB1- or ABCG2-overexpressing cells. Mitoxantrone 164-176 ATP binding cassette subfamily B member 1 Homo sapiens 180-185 17031644-2 2007 METHODS: Cellular content of mitoxantrone, a Pgp, MRP-1 and BCRP substrate, was measured by flow cytometry in cells overexpressing these proteins following incubation with and without CsA, tacrolimus or sirolimus. Mitoxantrone 29-41 ATP binding cassette subfamily B member 1 Homo sapiens 45-48 17031644-2 2007 METHODS: Cellular content of mitoxantrone, a Pgp, MRP-1 and BCRP substrate, was measured by flow cytometry in cells overexpressing these proteins following incubation with and without CsA, tacrolimus or sirolimus. Mitoxantrone 29-41 ATP binding cassette subfamily B member 1 Homo sapiens 50-55